{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:27:46Z","timestamp":1790033266823,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Chinese National Twelfth Five Years Project in Science and Technology","award":["2013ZX10002003"],"award-info":[{"award-number":["2013ZX10002003"]}]},{"name":"the Chinese National Thirteenth Five Years Project in Science and Technology","award":["2017ZX10202201"],"award-info":[{"award-number":["2017ZX10202201"]}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2018CFB206"],"award-info":[{"award-number":["2018CFB206"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12072-019-09956-1","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T13:02:27Z","timestamp":1559826147000},"page":"573-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study"],"prefix":"10.1007","volume":"13","author":[{"given":"Di","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanlong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaji","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2027-9593","authenticated-orcid":false,"given":"Qin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"issue":"Suppl 1","key":"9956_CR1","doi-asserted-by":"publisher","first-page":"i6","DOI":"10.1136\/gutjnl-2012-302056","volume":"61","author":"M Dandri","year":"2012","unstructured":"Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012;61(Suppl 1):i6\u201317","journal-title":"Gut"},{"key":"9956_CR2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1053\/gast.2002.36026","volume":"123","author":"YC Chen","year":"2002","unstructured":"Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002;123:1084\u20131089","journal-title":"Gastroenterology"},{"key":"9956_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","volume":"135","author":"EH Buster","year":"2008","unstructured":"Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459\u2013467","journal-title":"Gastroenterology"},{"key":"9956_CR4","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jhep.2009.01.016","volume":"50","author":"R Moucari","year":"2009","unstructured":"Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009;50:1084\u20131092","journal-title":"J Hepatol"},{"issue":"67","key":"9956_CR5","first-page":"370","volume":"2017","author":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;2017(67):370\u2013398","journal-title":"J Hepatol"},{"key":"9956_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1\u201398","journal-title":"Hepatol Int"},{"key":"9956_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, American Association for the Study of Liver D. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261\u2013283","journal-title":"Hepatology"},{"key":"9956_CR8","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682\u20132695","journal-title":"N Engl J Med"},{"key":"9956_CR9","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206\u20131217","journal-title":"N Engl J Med"},{"key":"9956_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.23327","volume":"51","author":"TT Chang","year":"2010","unstructured":"Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5\u00a0years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422\u2013430","journal-title":"Hepatology"},{"key":"9956_CR11","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442\u20132455","journal-title":"N Engl J Med"},{"key":"9956_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/apt.13694","volume":"44","author":"CL Lin","year":"2016","unstructured":"Lin CL, Kao JH. Review article: novel therapies for hepatitis B virus cure\u2014advances and perspectives. Aliment Pharmacol Ther 2016;44:213\u2013222","journal-title":"Aliment Pharmacol Ther"},{"issue":"134\u201344","key":"9956_CR13","first-page":"e10","volume":"150","author":"P Marcellin","year":"2016","unstructured":"Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis b surface antigen in patients with chronic hepatitis B. Gastroenterology 2016;150(134\u201344):e10","journal-title":"Gastroenterology"},{"key":"9956_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","volume":"61","author":"Q Ning","year":"2014","unstructured":"Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 2014;61:777\u2013784","journal-title":"J Hepatol"},{"key":"9956_CR15","first-page":"25","volume":"6","author":"P Hu","year":"2018","unstructured":"Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, et al. HBsAg loss with peg-interferon alfa-2a in hepatitis b patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol 2018;6:25\u201334","journal-title":"J Clin Transl Hepatol"},{"key":"9956_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jcv.2013.09.020","volume":"58","author":"D Ouzan","year":"2013","unstructured":"Ouzan D, Penaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol 2013;58:713\u2013717","journal-title":"J Clin Virol"},{"key":"9956_CR17","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1053\/j.gastro.2008.03.037","volume":"134","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, Zhang JY, Wherry EJ, Jin B, Xu B, Zou ZS, et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 2008;134:1938\u20131949","journal-title":"Gastroenterology"},{"issue":"963\u201373","key":"9956_CR18","first-page":"e9","volume":"143","author":"C Boni","year":"2012","unstructured":"Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012;143(963\u201373):e9","journal-title":"Gastroenterology"},{"key":"9956_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jhep.2012.09.029","volume":"58","author":"L Micco","year":"2013","unstructured":"Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 2013;58:225\u2013233","journal-title":"J Hepatol"},{"key":"9956_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2015.10.013","volume":"64","author":"A de Niet","year":"2016","unstructured":"de Niet A, Stelma F, Jansen L, Sinnige MJ, Remmerswaal EB, Takkenberg RB, et al. Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy. J Hepatol 2016;64:539\u2013546","journal-title":"J Hepatol"},{"key":"9956_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3851\/IMP2953","volume":"20","author":"W Yan","year":"2015","unstructured":"Yan W, Wu D, Wang X, Chen T, Lai Q, Zheng Q, et al. Upregulation of NKG2C\u2009+\u2009natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB. Antivir Ther 2015;20:591\u2013602","journal-title":"Antivir Ther"},{"key":"9956_CR22","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/apt.14629","volume":"47","author":"K Qiu","year":"2018","unstructured":"Qiu K, Liu B, Li SY, Li H, Chen ZW, Luo AR, et al. Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. Aliment Pharmacol Ther 2018;47:1340\u20131348","journal-title":"Aliment Pharmacol Ther"},{"key":"9956_CR23","doi-asserted-by":"publisher","first-page":"S771","DOI":"10.1093\/infdis\/jix355","volume":"216","author":"D Wu","year":"2017","unstructured":"Wu D, Ning Q. Toward a Cure for Hepatitis B Virus Infection: combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome. J Infect Dis 2017;216:S771\u2013S777","journal-title":"J Infect Dis"},{"key":"9956_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jhep.2012.11.007","volume":"58","author":"R Thimme","year":"2013","unstructured":"Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol 2013;58:205\u2013209","journal-title":"J Hepatol"},{"key":"9956_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jhep.2014.10.002","volume":"62","author":"D Wu","year":"2015","unstructured":"Wu D, Han M, Ning Q. An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: the future of chronic hepatitis B? J Hepatol 2015;62:240\u2013241","journal-title":"J Hepatol"},{"key":"9956_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jcv.2004.07.004","volume":"32","author":"N Horiike","year":"2005","unstructured":"Horiike N, Fazle Akbar SM, Michitaka K, Joukou K, Yamamoto K, Kojima N, et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005;32:156\u2013161","journal-title":"J Clin Virol"},{"key":"9956_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hep.1840080309","volume":"8","author":"S Kakumu","year":"1988","unstructured":"Kakumu S, Fuji A, Yoshioka K, Tahara H, Ohtani Y, Hirofuji H, et al. Pilot study of recombinant human interleukin 2 for chronic type B hepatitis. Hepatology 1988;8:487\u2013492","journal-title":"Hepatology"},{"key":"9956_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1086\/314828","volume":"180","author":"I Couillin","year":"1999","unstructured":"Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999;180:15\u201326","journal-title":"J Infect Dis"},{"key":"9956_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/jmv.2165","volume":"66","author":"A Dahmen","year":"2002","unstructured":"Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 2002;66:452\u2013460","journal-title":"J Med Virol"},{"key":"9956_CR30","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/hep.21282","volume":"44","author":"K Wursthorn","year":"2006","unstructured":"Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675\u2013684","journal-title":"Hepatology"},{"key":"9956_CR31","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/hep.23571","volume":"51","author":"AJ Thompson","year":"2010","unstructured":"Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933\u20131944","journal-title":"Hepatology"},{"key":"9956_CR32","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/hep.23844","volume":"52","author":"MJ Sonneveld","year":"2010","unstructured":"Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251\u20131257","journal-title":"Hepatology"},{"key":"9956_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/gutjnl-2011-301430","volume":"62","author":"P Lampertico","year":"2013","unstructured":"Lampertico P, Vigano M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, et al. Randomised study comparing 48 and 96\u00a0weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013;62:290\u2013298","journal-title":"Gut"},{"key":"9956_CR34","doi-asserted-by":"publisher","first-page":"13383","DOI":"10.1038\/s41598-017-13747-9","volume":"7","author":"J Huang","year":"2017","unstructured":"Huang J, Zhang K, Chen W, Liao J, Luo X, Chen R. Switching to PegIFNalpha-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs. Sci Rep 2017;7:13383","journal-title":"Sci Rep"},{"key":"9956_CR35","unstructured":"Honer Zu Siederdissen C, Cornberg M. The role of HBsAg levels in the current management of chronic HBV infection. Ann Gastroenterol 2014;27:105\u2013112"},{"key":"9956_CR36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","volume":"58","author":"S Chevaliez","year":"2013","unstructured":"Chevaliez S, Hezode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013;58:676\u2013683","journal-title":"J Hepatol"},{"key":"9956_CR37","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001\u20131010","journal-title":"N Engl J Med"},{"key":"9956_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1172\/JCI58847","volume":"122","author":"L Belloni","year":"2012","unstructured":"Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012;122:529\u2013537","journal-title":"J Clin Invest"},{"key":"9956_CR39","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"J Lucifora","year":"2014","unstructured":"Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221\u20131228","journal-title":"Science"},{"key":"9956_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3851\/IMP3019","volume":"21","author":"M Han","year":"2016","unstructured":"Han M, Jiang J, Hou J, Tan D, Sun Y, Zhao M, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-alpha2a: 1\u00a0year follow-up of the OSST study. Antivir Ther 2016;21:337\u2013344","journal-title":"Antivir Ther"},{"key":"9956_CR41","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/jvh.12018","volume":"20","author":"L Boglione","year":"2013","unstructured":"Boglione L, D\u2019Avolio A, Cariti G, Milia MG, Simiele M, De Nicolo A, et al. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat 2013;20:e11\u2013e19","journal-title":"J Viral Hepat"},{"key":"9956_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1365-2893.2010.01332.x","volume":"18","author":"R Moucari","year":"2011","unstructured":"Moucari R, Boyer N, Ripault MP, Castelnau C, Mackiewicz V, Dauvergne A, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepat 2011;18:580\u2013856","journal-title":"J Viral Hepat"},{"key":"9956_CR43","first-page":"438","volume":"82","author":"M Nishioka","year":"1987","unstructured":"Nishioka M, Kagawa H, Shirai M, Terada S, Watanabe S. Effects of human recombinant interleukin 2 in patients with chronic hepatitis B: a preliminary report. Am J Gastroenterol 1987;82:438\u2013442","journal-title":"Am J Gastroenterol"},{"key":"9956_CR44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/BF02799026","volume":"23","author":"Y Mizoguchi","year":"1988","unstructured":"Mizoguchi Y, Shin T, Sakagami Y, Seki S, Kuroki T, Kobayashi K, et al. Effects of recombinant interleukin 2 on immunological effector cells of the peripheral blood in patients with HBe antigen-positive chronic hepatitis. Gastroenterol Jpn 1988;23:147\u2013152","journal-title":"Gastroenterol Jpn"},{"key":"9956_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/(SICI)1096-9071(199803)54:3<167::AID-JMV4>3.0.CO;2-3","volume":"54","author":"S Artillo","year":"1998","unstructured":"Artillo S, Pastore G, Alberti A, Milella M, Santantonio T, Fattovich G, et al. Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. J Med Virol 1998;54:167\u2013172","journal-title":"J Med Virol"},{"issue":"Suppl 3","key":"9956_CR46","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/S0168-8278(05)80424-6","volume":"17","author":"HR Bruch","year":"1993","unstructured":"Bruch HR, Korn A, Klein H, Markus R, Malmus K, Baumgarten R, et al. Treatment of chronic hepatitis B with interferon alpha-2b and interleukin-2. J Hepatol 1993;17(Suppl 3):S52\u2013S55","journal-title":"J Hepatol"},{"key":"9956_CR47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2119\/molmed.2009.00035","volume":"15","author":"A Lunemann","year":"2009","unstructured":"Lunemann A, Lunemann JD, Munz C. Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med 2009;15:352\u2013358","journal-title":"Mol Med"},{"key":"9956_CR48","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/jvh.12946","volume":"25","author":"A Shi","year":"2018","unstructured":"Shi A, Zhang X, Xiao F, Zhu L, Yan W, Han M, et al. CD56(bright) natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2a. J Viral Hepat 2018;25:1352\u20131362","journal-title":"J Viral Hepat"},{"key":"9956_CR49","doi-asserted-by":"publisher","first-page":"e1005788","DOI":"10.1371\/journal.ppat.1005788","volume":"12","author":"US Gill","year":"2016","unstructured":"Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, et al. Interferon alpha induces sustained changes in NK cell responsiveness to hepatitis B viral load suppression in vivo. PLoS Pathog 2016;12:e1005788","journal-title":"PLoS Pathog"},{"key":"9956_CR50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/hep.29155","volume":"66","author":"AD Kosinska","year":"2017","unstructured":"Kosinska AD, Pishraft-Sabet L, Wu W, Fang Z, Lenart M, Chen J, et al. Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models. Hepatology 2017;66:69\u201383","journal-title":"Hepatology"},{"key":"9956_CR51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0168-8278(05)80580-X","volume":"19","author":"H Tilg","year":"1993","unstructured":"Tilg H, Vogel W, Tratkiewicz J, Aulitzky WE, Herold M, Gruber M, et al. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B immunomodulatory and antiviral effects. J Hepatol 1993;19:259\u2013267","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-019-09956-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T19:27:41Z","timestamp":1591298861000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-019-09956-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["9956"],"URL":"https:\/\/doi.org\/10.1007\/s12072-019-09956-1","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,6]]},"assertion":[{"value":"28 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with Good Clinical Practice and the Declaration of Helsinki principles for ethical research. The study protocol was approved by the independent central ethics committee of Tongji Medical College at Wuhan. Written informed consent was obtained from each participant. ClinicalTrials.gov Identifier: NCT02360592. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}